Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866479 | 0.86 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3CYP3A4 | |
| SCHEMBL13866480 | 0.82 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BADORA3CYP3A4 | |
| SCHEMBL13866481 | 0.80 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BADORA3CYP3A4 | |
| SCHEMBL4564902 | 0.77 | CDK1 (0.46) | CYP3A4ALOX15TSHRMAPK1KDM4E | |
| SCHEMBL716062 | 0.77 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BADORA3CYP3A4 | |
| SCHEMBL4564695 | 0.75 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL409917 | 0.72 | ADORA2A (0.57) | ADORA2AADORA1ADORA2BADORA3CYP3A4 | |
| SCHEMBL407814 | 0.72 | CCNE2 (0.43) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL13866478 | 0.68 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BCYP3A4ALOX15 | |
| SCHEMBL4454079 | 0.68 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528252-B2 | Derivatives of triazoly-imidazopyridine useful as ligands of the adenosine A2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-05-05 | — | — | US | disclosed |
| US-20070249638-A1 | Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-10-25 | — | — | US | disclosed |
| US-7230102-B2 | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-06-12 | — | — | US | disclosed |
| EP-1412354-B1 | DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A 2a? RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2006-05-10 | — | — | EP | disclosed |
| US-20040204428-A1 | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-10-14 | — | — | US | disclosed |
| EP-1412354-A1 | DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A 2a? RECEPTOR AND THEIR USE AS MEDICAMENTS | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011864-A1 | DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2a RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249638-A1 | Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA2B 4/4885 |
| US-20040204428-A1 | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.